Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17015657 | 0.94 | KDM4E (0.35) | MAPK9MAPK10BIRC5KDM4EATM | |
| SCHEMBL17015191 | 0.94 | KDM4E (0.38) | MAPK9MAPK10BIRC5KDM4EATM | |
| SCHEMBL17015658 | 0.93 | WNK1 (0.33) | BIRC5KDM4EATML3MBTL1HTR7 | |
| SCHEMBL17015741 | 0.93 | MAPK9 (0.32) | MAPK9MAPK10KDM4EATML3MBTL1 | |
| SCHEMBL17015647 | 0.93 | PDPK1 (0.33) | MAPK9MAPK10BIRC5KDM4EATM | |
| SCHEMBL17016140 | 0.92 | KDM4E (0.38) | MAPK9MAPK10BIRC5KDM4EATM | |
| SCHEMBL17015193 | 0.92 | KDM4E (0.38) | MAPK9MAPK10BIRC5KDM4EATM | |
| SCHEMBL17015194 | 0.91 | KDM4E (0.34) | KDM4EATML3MBTL1KMT2A | |
| SCHEMBL16357493 | 0.90 | KDM4E (0.39) | MAPK9MAPK10BIRC5KDM4EATM | |
| SCHEMBL17016141 | 0.89 | KDM4E (0.41) | MAPK9MAPK10BIRC5KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | INMT, IDO1, IDO2 | MAPK9 2083/4885MAPK10 1470/4885BIRC5 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.